Trump administration declines to expand Medicare coverage for obesity drugs
The Trump administration's Center for Medicare and Medicaid Services (CMS) has chosen not to finalize a rule proposed by the Biden administration in November that would have allowed Medicare to cover weight loss drugs such as Wegovy and Zepbound for obesity alone for anyone insured by the federal programs.
The rule was expected to increase federal spending by $25 billion for Medicare and $15 billion for Medicaid over the next 10 years.
In a statement, the agency told ABC News extending coverage of anti-obesity medications under Medicare Part D and Medicaid "is not appropriate at this time."
State Medicaid programs can still decide if they will cover the medications.
Medicare, which provides health coverage for those over 65, currently covers these drugs to treat diabetes and to treat heart complications but not for weight loss alone.
-ABC News' Eric Strauss





